Suggested remit: To appraise the clinical and cost effectiveness of dabrafenib with trametinib within its marketing authorisation for treating BRAF V600E mutation-positive glioma in children and young people aged 1 to 17.
Status
|
In progress
|
Technology type
|
Medicine
|
Decision
|
Selected
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
Process |
STA Standard
|
ID number |
5104
|
Provisional Schedule
Final draft guidance |
24 April 2024 - 09 May 2024 |
Expected publication |
29 May 2024 |
Project Team
Project lead |
Thomas Feist |
Email enquiries
External Assessment Group |
School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
Companies sponsors |
Novartis |
Others |
Department of Health and Social Care |
|
Health Technology Wales (HTW) |
|
NHS England |
Patient carer groups |
The Brain Tumour Charity |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Physicians |
|
Royal College of Radiologists |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |
Date
|
Update
|
12 March 2024
|
Committee meeting: 1 |
08 August 2023
|
Invitation to participate |
06 July 2023 (10:00)
|
Scoping workshop |
15 May 2023 - 13 June 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5104 |
07 July 2022
|
In progress. DHSC referral received |
30 March 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual